NPO Microgen of the National Immunobiological Company, a part of Rostec Corporation, started phase 2 clinical trials of Difag. The drug is a bacteriophage, a non-toxic agent that selectively affects only the bacterial cells.
Unlike antibiotics, new bacteriophage has a targeted action and can be safely used to treat special categories of patients, including pregnant and lactating women, as well as newborns.
“Russian pharmaceutical industry is one of the global leaders in manufacturing of bacteriophages. Our latest products have the potential of not only capturing a dominant share in the Russian market of medicines against bacteria, but also can be successfully exported. The clinical trials of latest drug will be completed by the end of 2018,” said Oleg Yevtushenko, Executive Director of Rostec Corporation.
The current phase of Difag trials is aimed at confirming safety and assessing therapeutic efficacy in patients with surgical infections of skin and soft tissues caused by Pseudomonas aeruginosa and Acinetobacterbaumannii. Difag acts on Acinetobacterbaumannii and Pseudomonas aeruginosa, which are the most frequent cause of infectious diseases in patients of surgical hospitals, intensive care and intensive treatment units.